Clinical Trial Update: Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies [Phase 4]

View source ↗

Summary

Phase 4 trial update for ubrogepant in migraine patients using monoclonal antibodies; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Ubrelvy (ubrogepant)

Snippet

Sponsor: Chicago Headache Center & Research Institute | Conditions: Headache, Migraine | Phase 4 | Status: ACTIVE_NOT_RECRUITING